会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • ADENOVIRAL VECTOR COMPOSITIONS
    • 腺病毒载体组合物
    • WO2006020480A3
    • 2006-11-23
    • PCT/US2005027658
    • 2005-08-05
    • MERCK & CO INCEMINI EMILIO ASHIVER JOHN WCASIMIRO DANILO RBETT ANDREW J
    • EMINI EMILIO ASHIVER JOHN WCASIMIRO DANILO RBETT ANDREW J
    • C12N15/00A61K39/12A61K49/00C12N7/00
    • C12N15/86A61K39/12A61K39/21A61K48/00A61K48/0083A61K2039/53A61K2039/545A61K2039/57C07K14/005C12N7/00C12N2710/10343C12N2740/16134C12N2740/16334
    • Applicants disclose herein novel methods, vectors, and vector compositions for improving the efficiency of adenoviral vectors in the delivery and expression of heterologous nucleic acid encoding a polypeptide(s) (e.g, a protein or antigen) of interest. Adenoviral infection is quite common in the general population, and a large percentage of people have neutralizing antibodies to the more prevalent adenoviral serotypes. Such pre-existing anti-adenoviral immunity can dampen or possibly abrogate the effectiveness of this virus for the delivery and expression of heterologous proteins or antigens. The method taught herein functions to offset pre-existing immunity through the delivery of the protein or antigen by a cocktail of at least two adenoviral serotypes. Utilizing a composition of at least two adenoviral serotypes in this manner has been found to increase the effectiveness of adenoviral administration. Adenoviral vectors of utility in the elicitation of an immune response against Human Immunodeficiency Virus ("HIV") are also disclosed.
    • 申请人在此公开用于提高腺病毒载体在递送和表达编码感兴趣的多肽(例如,蛋白质或抗原)的异源核酸的表达中的效率的新颖方法,载体和载体组合物。 腺病毒感染在普通人群中相当常见,并且大部分人具有针对更普遍的腺病毒血清型的中和抗体。 这种预先存在的抗腺病毒免疫力可抑制或可能消除该病毒对异源蛋白质或抗原递送和表达的有效性。 本文教导的方法用于通过由至少两种腺病毒血清型的混合物递送蛋白质或抗原来抵消预先存在的免疫性。 已经发现以这种方式利用至少两种腺病毒血清型的组合物可以增加腺病毒给药的有效性。 也公开了用于引发针对人类免疫缺陷病毒(“HIV”)的免疫应答的腺病毒载体。
    • 9. 发明申请
    • ENHANCED FIRST GENERATION ADENOVIRUS VACCINES EXPRESSING CODON OPTIMIZED HIV1-GAG, POL, NEF AND MODIFICATIONS
    • 表达密码子优化的HIV1-GAG,POL,NEF和修饰的增强的第一代腺病毒疫苗
    • WO0222080A8
    • 2003-01-16
    • PCT/US0128861
    • 2001-09-14
    • MERCK & CO INCEMINI EMILIO AYOUIL RIMABETT ANDREW JCHEN LINGKASLOW DAVID CSHIVER JOHN WTONER TIMOTHY JCASIMIRO DANIEL R
    • EMINI EMILIO AYOUIL RIMABETT ANDREW JCHEN LINGKASLOW DAVID CSHIVER JOHN WTONER TIMOTHY JCASIMIRO DANIEL R
    • C12N15/09A61K35/76A61K38/00A61K39/235A61K48/00A61P31/18A61P37/04C07K14/16C12N5/10C12N7/00C12N7/02C12N15/861C12R1/93C12N15/86
    • C12N7/00A61K2039/5256A61K2039/53A61K2039/545A61K2039/57C07K14/005C12N15/86C12N2710/10343C12N2710/10351C12N2740/16134C12N2740/16334C12N2830/42
    • First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV1- Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, encoding codon optimized HIV-1 Pol, derivatives of optimized HIV-1 Pol (including constructs wherein protease, reverse transcriptase, RNAse H and integrase activity of HIV-1 Pol is inactivated), HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef mutants which effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4. The adenoviral vaccines of the present invention, when administered alone or in a combined modality regime, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.
    • 本说明书中描述了第一代腺病毒载体和相关的基于重组腺病毒的HIV疫苗,其显示增强的稳定性和生长特性以及更大的细胞介导的免疫性。 这些腺病毒载体被用于通过细胞培养产生并产生含有HIV-1 gag,HIV-1 pol和/或HIV-1 nef多核苷酸药物产品的各种基于腺病毒的HIV-1疫苗及其生物学相关的修饰。 这些腺病毒疫苗当直接引入活脊椎动物组织时,优选哺乳动物宿主如具有商业或家庭兽医重要性的人或非人哺乳动物,表达HIV1-Gag,Pol和/或Nef蛋白或其生物学修饰, 诱导特异性识别HIV-1的细胞免疫应答。 本发明的示例性多核苷酸是编码HIV-1 Gag的编码密码子优化的HIV-1 Pol的合成DNA分子,优化的HIV-1 Pol的衍生物(包括其中蛋白酶,逆转录酶,RNA酶H和HIV-1整合酶活性的构建体 Pol失活),HIV-1 Nef和优化的HIV-1 Nef的衍生物,包括影响Nef的野生型特征的nef突变体,例如十四烷酸化和下调宿主CD4。 本发明的腺病毒疫苗当单独或以联合形式方案给药时,将为先前未感染的个体提供预防性益处和/或通过降低感染个体内的病毒载量水平来提供治疗效果,从而延长无症状阶段 HIV-1感染。
    • 10. 发明申请
    • ENHANCED FIRST GENERATION ADENOVIRUS VACCINES EXPRESSING CODON OPTIMIZED HIV1-GAG, POL, NEF AND MODIFICATIONS
    • 增强第一代艾滋病毒疫苗,表达优化的HIV1-GAG,POL,NEF和改良的代码
    • WO0222080A3
    • 2002-05-02
    • PCT/US0128861
    • 2001-09-14
    • MERCK & CO INCEMINI EMILIO AYOUIL RIMABETT ANDREW JCHEN LINGKASLOW DAVID CSHIVER JOHN WTONER TIMOTHY JCASIMIRO DANIEL R
    • EMINI EMILIO AYOUIL RIMABETT ANDREW JCHEN LINGKASLOW DAVID CSHIVER JOHN WTONER TIMOTHY JCASIMIRO DANIEL R
    • C12N15/09A61K35/76A61K38/00A61K39/235A61K48/00A61P31/18A61P37/04C07K14/16C12N5/10C12N7/00C12N7/02C12N15/861C12R1/93C12N15/86
    • C12N7/00A61K2039/5256A61K2039/53A61K2039/545A61K2039/57C07K14/005C12N15/86C12N2710/10343C12N2710/10351C12N2740/16134C12N2740/16334C12N2830/42
    • First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV1- Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, encoding codon optimized HIV-1 Pol, derivatives of optimized HIV-1 Pol (including constructs wherein protease, reverse transcriptase, RNAse H and integrase activity of HIV-1 Pol is inactivated), HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef mutants which effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4. The adenoviral vaccines of the present invention, when administered alone or in a combined modality regime, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.
    • 在本说明书中描述了显示增强的稳定性和生长特性以及更大的细胞介导的免疫的第一代腺病毒载体和相关重组腺病毒的HIV疫苗。 这些腺病毒载体用于通过细胞培养产生和产生各种含有HIV-1 gag,HIV-1 pol和/或HIV-1 nef多核苷酸药物产品的基于腺病毒的HIV-1疫苗及其生物相关的修饰。 这些腺病毒疫苗当直接引入活的脊椎动物组织中时,优选哺乳动物宿主例如具有商业或家庭兽医重要性的人或非人哺乳动物,表达HIV1-Gag,Pol和/或Nef蛋白或其生物修饰, 诱导特异性识别HIV-1的细胞免疫应答。 本发明的示例性多核苷酸是编码HIV-1Gag的编码密码子优化的HIV-1 Pol的合成DNA分子,其优化的HIV-1 Pol的衍生物(包括其中蛋白酶,逆转录酶,RNAse H和HIV-1的整合酶活性的构建体 Pol被灭活),HIV-1 Nef和优化的HIV-1 Nef的衍生物,包括影响Nef野生型特征的nef突变体,如主体CD4的肉豆蔻酰化和下调。 本发明的腺病毒疫苗当单独施用或以组合的方式给药时,将对先前未感染的个体提供预防优势,和/或通过减少被感染个体内的病毒载量水平提供治疗效果,从而延长无症状期 HIV-1感染。